3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
228
Other
4
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
30
Docetaxel
10
Cetuximab
10
Trastuzumab
9
Paclitaxel
7
Nivolumab
6
Magnetic Resonance Spectroscopy
6
palbociclib
5
cemiplimab
5
Gemcitabine
5
Cyclophosphamide
5
Carboplatin
5
Capecitabine
5
Biopsy
5
durvalumab
4
atezolizumab
4
Surveys and Questionnaires
4
Radiotherapy
4
Fulvestrant
4
Fluorodeoxyglucose F18
4
Drug Therapy
4
Cisplatin
4
selpercatinib
3
poly ICLC
3
pazopanib
3
fludarabine
3
avelumab
3
Taxes
3
Sunitinib
3
Specimen Handling
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
exemestane
×
Head & Neck
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled